LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Electronic Nose Sniffs Out Prostate Cancer

By LabMedica International staff writers
Posted on 19 May 2014
Image: The ChemPro100 Handheld Chemical Detector (eNose) (Photo courtesy of Environics).
Image: The ChemPro100 Handheld Chemical Detector (eNose) (Photo courtesy of Environics).
Soon it may be possible to make a rapid, early diagnosis of prostate cancer using a noninvasive electronic nose that sniffs a urine sample.

Prostate cancer is the second most common malignancy in men and one of the leading causes of death from cancer and it is difficult to diagnose and make reliable prognoses about the disease because it does not appear consistently in prostate tissue.

Scientists at the University of Tampere (Finland) tested 50 patients with confirmed prostate cancer and 24 samples from 15 patients with benign prostatic hyperplasia. Fifteen patients provided urine preoperatively and nine patients provided samples three months postoperatively and all patients were scheduled to undergo robotic assisted laparoscopic radical prostatectomy or transurethral resection of the prostate.

The electronic nose or eNose used in the study was a commercially available model ChemPro100 (Environics Inc.; Mikkeli, Finland) based on the ion mobility spectrometry principle. The device contains an ion mobility cell that consists of eight electrode strips producing two-channel output and a metal oxide based semiconductor cell. Together these sensors produce 18-channel measurement data. The sensors do not specify molecules, but produce a characteristic smell print of the sample.

The team found that the eNose, which analyzed molecules in the urine headspace, was able to discriminate prostate cancer from benign prostatic hyperplasia with a sensitivity of 78% and a specificity of 67%, on a par with the prostate specific antigen (PSA) tests. Niku Oksala, MD, PhD, DSc, the senior author of the study said, “PSA is known to correlate positively with prostate volume, which is a potential source of diagnostic error when comparing prostate cancer with benign disease. According to our current analysis, prostate volume did not affect the eNose results, potentially indicating high specificity of our sensor array to cancer.” The study was published online on February 25, 2014, in the Journal of Urology.

Related Links:

University of Tampere
Environics Inc.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Automated MALDI-TOF MS System
EXS 3000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more